Back to Research Hub
argenx SE
ARGX
$884.00+1.59 (+0.18%)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
StreetsValue research for argenx SE (ARGX)
Members get the full report for argenx SE: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.